Welcome to our dedicated page for INVO Fertility SEC filings (Ticker: IVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The INVO Fertility, Inc. (Nasdaq: IVF) SEC filings page provides access to the company’s regulatory disclosures as a Nevada-incorporated healthcare services fertility company. Through these documents, investors can review how INVO Fertility reports on its fertility clinic operations, INVOcell device activities, financing transactions, and governance matters.
Key filings for IVF include annual and quarterly reports on Forms 10-K and 10-Q, which present financial statements, management’s discussion and analysis, and segment information distinguishing clinic revenue from product revenue related to INVOcell. These reports also describe the company’s focus on building, acquiring, and operating fertility clinics, its two INVO Centers and one IVF clinic, and its ongoing sale and distribution of the INVOcell device to third-party clinics.
Investors can also examine current reports on Form 8-K, where INVO Fertility discloses material events such as the asset purchase agreement to acquire the non-clinical assets of Family Beginnings in Indiana, settlement agreements related to clinic acquisitions, unregistered sales of equity securities, and the implementation of a 1-for-8 reverse stock split. These filings provide timely detail on acquisitions, capital structure changes, and other significant corporate actions.
Registration statements on Form S-1 outline the terms under which existing security holders may resell shares of common stock, including those issuable upon conversion of Series C-2 Non-Voting Convertible Preferred Stock or exercise of warrants. Proxy materials on Schedule 14A describe proposals such as auditor ratification, increases in authorized common stock, and amendments to stock incentive plans, along with information on security ownership and executive and director compensation.
On this page, AI-powered tools can help summarize lengthy filings, highlight important sections in annual reports (10-K) and quarterly reports (10-Q), and make it easier to understand complex financing structures and warrant terms. Users can also monitor insider-related and capital structure disclosures through the company’s 8-K and S-1 filings, and track how these regulatory documents relate to the IVF stock and its fertility-focused business model.
Steven Shum, listed as Chief Executive Officer and a Director of INVO Fertility, Inc. (IVF), filed a Form 4 reporting an equity compensation transaction dated 08/26/2025. The filing shows a grant of a stock option with an exercise price of $1.01 covering 42,000 underlying shares, exercisable through 08/26/2035. The option vests in four equal installments beginning on the first day of the calendar quarter following 08/26/2025 and on the first day of each calendar quarter thereafter until fully vested. Following the reported transaction, the filing lists beneficial ownership of 42,451 shares of common stock held directly.
INVO Fertility, Inc. entered into an Exchange Agreement with Five Narrow Lane LP on September 29, 2025. FNL agreed to exchange a Second Amended and Restated Senior Secured Convertible Debenture due February 11, 2026 for shares of Series C-2 Convertible Preferred Stock with an aggregated stated value of 1,334,000, and the company agreed to issue 467 additional shares of Series C-2 Preferred Stock to FNL. As a result of this transaction, the debenture has been paid in full and fully extinguished. The issuance of the Series C-2 Preferred Stock was made as an unregistered sale of equity securities in reliance on Sections 3(a)(9) and 4(a)(2) of the Securities Act of 1933.